Paulo Araújo, a 38-year-old logistics operator from Bahia, has become the second patient in the state to undergo an innovative treatment with polylaminin, a promising enzyme for acute spinal cord injuries. This experimental procedure was conducted at the Hospital Mater Dei Salvador (HMDS) and is notable as it is the first case executed in a private hospital under a research protocol approved by the National Health Surveillance Agency (Anvisa).

Paulo's journey took a dramatic turn in December 2025 when he was shot during a robbery attempt, resulting in a complete spinal cord injury at the T2 vertebra level, leading to paralysis from the chest down. This tragic event deeply affected his life, but Paulo’s discovery of the polylaminin treatment revived his hope for recovery. Inspired by a report detailing the treatment's benefits, he reached out for assistance to access this new medical option.

The use of polylaminin is part of ongoing research to address the challenges of spinal injuries. This situation not only highlights Paulo's personal struggle but also emphasizes the importance of advancing medical treatments in Brazil, fostering trust in scientific breakthroughs and enhancing patient care within the field of neurology. As more patients gain access to such advancements, it could signify a significant shift in how spinal injuries are treated in the country, bringing renewed hope to many.